King Pharmaceuticals LLC Sustainability Profile
King Pharmaceuticals LLC, headquartered in the United States, is a prominent player in the pharmaceutical industry, specialising in the development and marketing of innovative therapeutic solutions. Founded in 1994, the company has achieved significant milestones, including strategic acquisitions that have expanded its portfolio and market reach. With a focus on pain management and other critical therapeutic areas, King Pharmaceuticals offers a range of unique products that address unmet medical needs. Their commitment to quality and innovation has positioned them as a trusted name in the healthcare sector. Notably, the company has garnered recognition for its contributions to patient care, solidifying its status as a leader in the pharmaceutical landscape.
DitchCarbon Score
How does King Pharmaceuticals LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
King Pharmaceuticals LLC's score of 84 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
King Pharmaceuticals LLC, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. However, the company is part of a corporate family relationship with Pfizer Inc., which influences its climate commitments and initiatives. King Pharmaceuticals inherits its climate strategies and targets from Pfizer Inc., a leader in the pharmaceutical industry. Pfizer has established significant climate commitments, including science-based targets for emissions reductions, which are cascaded down to its subsidiaries like King Pharmaceuticals. These initiatives include participation in the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all aimed at enhancing sustainability and reducing carbon footprints. While specific reduction targets for King Pharmaceuticals are not detailed, the overarching goals set by Pfizer Inc. reflect a commitment to addressing climate change and reducing greenhouse gas emissions across its operations. As a current subsidiary, King Pharmaceuticals aligns with these industry-standard climate strategies, contributing to a broader effort to mitigate environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 964,846,000 | - | - | - | - | - | - | - | 000,000,000 | - | - | - | 000,000,000 |
| Scope 2 | 883,814,000 | - | - | - | - | - | - | - | 000,000,000 | - | - | - | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 000,000,000 | 0,000,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 0,000,000,000 |
How Carbon Intensive is King Pharmaceuticals LLC's Industry?
How Carbon Intensive is King Pharmaceuticals LLC's Location?
King Pharmaceuticals LLC's Scope 3 Categories Breakdown
King Pharmaceuticals LLC's Scope 3 emissions, which increased significantly last year and increased by approximately 821% since 2019, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 77% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 79% of Scope 3 emissions.
Top Scope 3 Categories
King Pharmaceuticals LLC's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
King Pharmaceuticals LLC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
